drugset / Trial / NCT07480941
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a draft, ClinicalTrials.gov-style example record for a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent or progressive glioblastoma (GBM) or other high-grade glioma (HGG). Participants will undergo tumor antigen profiling for IL13Rα2, EGFR/EGFRvIII, and B7-H3 (CD276). Based on this assessment, each participant will receive the most suitable dual-target CAR construct to reduce antigen-escape risk.
Timeline
- Start
- 2026-02-02
- Primary completion
- 2027-02-18
- Completion
- 2028-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dual-target CAR-NK cells | Cell therapy | 1e+07 cells | Other |
| Subject | Dual-target CAR-NK cells | Cell therapy | 3e+07 cells | Other |
| Subject | Dual-target CAR-NK cells | Cell therapy | 1e+08 cells | Other |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |